[8-K] Moleculin Biotech, Inc. Reports Material Event

Rhea-AI Filing Summary

Moleculin Biotech, Inc. (MBRX) filed a Form 8-K reporting a Regulation FD disclosure that the company posted an investor presentation dated August 2025 to its website and furnished the presentation as Exhibit 99.1. The filing clarifies the furnished exhibit is not being "filed" under the Securities Exchange Act and will not be incorporated by reference into other SEC filings unless expressly stated. No financial results, transactions, or forward-looking guidance are included in this report.

Positive

• Investor presentation furnished as Exhibit 99.1, making updated corporate materials publicly available
• Regulation FD compliance demonstrated by furnishing the presentation to ensure broad access to investor information

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine Regulation FD furnishing of an investor presentation; provides updated investor materials but no new financial data.

The company furnished an investor presentation as Exhibit 99.1, consistent with standard disclosure practice to ensure broad investor access to corporate materials. Because the presentation is furnished rather than filed, it does not carry the same incorporation implications for future SEC filings. There are no earnings, transaction, or material operational updates in this 8-K, so immediate valuation impact is likely minimal.

Corporate Governance Expert

TL;DR: Disclosure aligns with Regulation FD obligations and improves transparency without creating new reporting obligations.

Furnishing the investor presentation meets fair disclosure expectations by making investor-facing materials publicly available. The explicit statement that the exhibit is furnished and not filed is an important legal distinction that limits incorporation by reference. This is a governance-appropriate step to update stakeholders while avoiding inadvertent expansion of SEC filing liabilities.

false 0001659617 0001659617 2025-08-18 2025-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): August 18, 2025

MOLECULIN BIOTECH, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	001-37758	47-4671997
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File No.)	(I.R.S. Employer Identification No.)

5300 Memorial Drive, Suite 950, Houston, TX 77007

(Address of principal executive offices and zip code)

(713) 300-5160

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).          Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol (s)	Name of each exchange on which registered
Common Stock, par value $.001 per share	MBRX	The NASDAQ Stock Market LLC

Item 7.01 Regulation FD Disclosure

On August 18, 2025, Moleculin Biotech, Inc. (the “Company”) is using the attached presentation for its corporate presentation posted on the Company’s website and is set forth as Exhibit 99.1 herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 InvestorPresentation dated August 2025

104 Cover page Interactive Data File (formatted as Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MOLECULIN BIOTECH, INC.
	Date:	August 18, 2025
	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster

FAQ

What did Moleculin Biotech (MBRX) disclose in the August 18, 2025 Form 8-K?

The company furnished an investor presentation dated August 2025 as Exhibit 99.1 and stated the presentation is being furnished, not filed.

Does the Form 8-K include financial results or transactions for MBRX?

No. The filing contains no financial statements, earnings data, material transactions, or forward-looking guidance.

Is the investor presentation incorporated by reference into other SEC filings?

No. The filing explicitly states the furnished presentation is not being filed and will not be incorporated by reference unless specifically identified.

Where can investors find the Exhibit 99.1 investor presentation for MBRX?

The presentation was posted on the company's website and furnished as Exhibit 99.1 to the Form 8-K.

Does this 8-K indicate any emerging growth company status changes for MBRX?

The filing includes the emerging growth company checkbox area but does not indicate a change or provide further detail.